Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease

Fineline Cube Jan 19, 2026
Company Deals

InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline

Fineline Cube Jan 16, 2026
Company Deals

Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership

Fineline Cube Jan 16, 2026
Company Deals

J&J MedTech Partners with CED Medical to Accelerate Neurovascular Intervention Solutions

Fineline Cube Jan 16, 2026
Company Deals

Cardiac Bio Solutions Launches MyCardia AT China Production with Shenzhen Ebulent

Fineline Cube Jan 16, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Duality’s DB‑1317 ADC Receives IND Approval for ADAM9‑Targeted Solid Tumor Therapy

Fineline Cube Jan 19, 2026
Company Drug

Biogen’s High‑Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod

Fineline Cube Jan 19, 2026
Company Deals

Adicon Holdings Acquires Suzhou Youqin Medical Laboratory and Yuande Weikang

Fineline Cube May 8, 2025

China-based independent clinic laboratory (ICL) service provider Adicon Holdings Ltd (HKG: 9860) announced the acquisition...

Company Deals

Oricell Partners with Umoja Biopharma to Develop In Vivo CAR-T Cell Therapies

Fineline Cube May 8, 2025

China-based Oricell Therapeutics Co., Ltd. announced a strategic partnership agreement with US-headquartered Umoja Biopharma Inc....

Company

BeiGene’s Q1 2025 Revenues Soar 49% YOY, Driven by Brukinsa Global Sales

Fineline Cube May 8, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change...

Company Drug

European Commission Approves J&J’s Tremfya for Crohn’s Disease Treatment

Fineline Cube May 8, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced that the European Commission (EC) has approved Tremfya...

Company

Amgen Reports 9% Revenue Growth in Q1 2025, Driven by Double-Digit Product Sales

Fineline Cube May 8, 2025

US biotech Amgen (NASDAQ: AMGN) revealed its 2025 Q1 financial results, recording USD 8.1 billion...

Company Drug

AstraZeneca and Daiichi Sankyo Announce Positive DESTINY-Breast11 Trial Results for Enhertu

Fineline Cube May 8, 2025

Partners AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced the positive preliminary results from...

Company

Siemens Healthineers Reports Q2 2025 Revenue Up 6.8% to EUR 5.909 Billion

Fineline Cube May 8, 2025

Germany-based Siemens Healthineers AG (ETR: SHL) released its financial report for the second quarter of...

Company Drug

Grand Pharma Receives NMPA Review for Phase III Trial of TLX591 in Prostate Cancer

Fineline Cube May 8, 2025

China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced that a filing to conduct a Phase...

Company

Biogen Reports 8% YOY Sales Growth in Q1 2025, Driven by Rare Disease Therapies

Fineline Cube May 7, 2025

According to Biogen Inc.’s (NASDAQ: BIIB) Q1 2025 report released this week, the US firm...

Company Drug

Zhongsheng Pharma’s RAY1225 Shows Positive Results in Phase II Trials for Weight Loss and Blood Glucose Reduction

Fineline Cube May 7, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive top-line analysis results from dose...

Company Deals

Alchemab Therapeutics Licenses ATLX-1282 to Eli Lilly for ALS Treatment

Fineline Cube May 7, 2025

UK-based biotech Alchemab Therapeutics Ltd entered into a licensing agreement with US major Eli Lilly...

Policy / Regulatory

China’s NMPA Releases Draft Guidelines for Development Risk Management Plan

Fineline Cube May 7, 2025

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released the...

Company Drug

AstraZeneca’s Calquence Gains EU Approval for Mantle Cell Lymphoma

Fineline Cube May 7, 2025

UK-based pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) announced receiving another indication approval in the European...

Company Drug

Huadong Medicine’s HDM2005 Receives NMPA Approval for DLBCL Clinical Trial

Fineline Cube May 7, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...

Company

Fresenius Medical Care Reports 1% Revenue Growth in Q1 2025

Fineline Cube May 7, 2025

Germany-based Fresenius Medical Care (FRA: FMEA) released its 2025 Q1 financial report, showing total revenues...

Company Drug

Innovent Biologics Completes First Dosing in Phase II Study for Efdamrofusp Alfa in DME

Fineline Cube May 7, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced the completion of the first patient dosing in...

Company Deals

EndoCell Secures RMB 200 Million in Financing to Advance Islet Regeneration Technology

Fineline Cube May 7, 2025

EndoCell Biotech, a Shanghai-based developer of regenerated islet technology, reportedly completed Series A and Pre-Series...

Company Medical Device

Beijing Wantai’s HIV Urine Self-Test Kit Gains WHO Prequalification

Fineline Cube May 7, 2025

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) announced that its HIV urine...

Company Deals

Formosa Pharmaceuticals Licenses Clobetasol Propionate to Apotex for Mexico

Fineline Cube May 7, 2025

Taiwan-based Formosa Pharmaceuticals (TPE: 6838) announced an exclusive licensing agreement with Apotex Inc., granting the...

Company Drug

Shuangcheng Pharma’s Generic Bivalirudin Approved by Australia’s TGA

Fineline Cube May 7, 2025

China-based Hainan Shuangcheng Pharmaceutical Co., Ltd (SHE: 002693) announced that the market filing for its...

Posts pagination

1 … 111 112 113 … 611

Recent updates

  • Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease
  • Duality’s DB‑1317 ADC Receives IND Approval for ADAM9‑Targeted Solid Tumor Therapy
  • Biogen’s High‑Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod
  • InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline
  • Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease

Company Drug

Duality’s DB‑1317 ADC Receives IND Approval for ADAM9‑Targeted Solid Tumor Therapy

Company Drug

Biogen’s High‑Dose SPINRAZA Wins EU Approval for 5q SMA After Japan Nod

Company Deals

InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.